 InspireMD, Inc. NYSE American: NSPR, the developer of the CGuardTM Embolic Prevention System EPS for the prevention of stroke caused by carotid artery disease CAD, today announced strong preliminary unaudited revenue for the fourth quarter and reported an inducement grant to the companys new Chief Executive Officer, Marvin Slosman, who assumed the role effective January 1, 2020. InspireMD anticipates that preliminary unaudited revenue for the fourth quarter ended December 31, 2019, will be within a range of 1,000,000 to 1,025,000, representing estimated growth of 22-25 over the comparable period in 2018. 